Tech article
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Publisher description: The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
TechCrunch | Sep 23, 2026 | Marina Temkin
Automated excerpt
Enveda, a biotech startup that uses AI to discover new drugs in the natural world, has raised a $311 million Series E at a $2 billion valuation. The fresh funding, which was led by Catalio Capital Management, with participation from Iconiq and others, doubles the valuation Enveda achieved 12 months ago. While AI hasn’t yet produced any FDA-approved drugs, Enveda is among the wave of companies advancing AI-discovered candidates into human clinical trials.
Selected automatically from source text; not independently written or fact-checked. Read the original for full context.